Identification of Novel Features to Assess Risk and Improve Therapeutic Decision Making for Prostate Cancer Through a Novel High-Parameter Imaging System
Abstract
About 15 percent of men will be diagnosed with prostate cancer and many will face difficult treatment decisions. This projects goal is to develop and apply a novel imaging strategy that increases the information and potential clinical utility from prostate biopsy samples. Combining two high-dimensional imaging methods: antibody-based imaging mass cytometry (IMC), and mass spectroscopy imaging (MSI) that are layered together, the goal is to generate exceptionally detailed maps of the cells, molecules, and structures from tumor samples. These layered multi-modal images can be used to identify markers that improve assessments of risk and may ultimately inform clinical decisions. In the first year of the project, despite challenges resulting from the COVID 19 pandemic, we are nearing completion of method development and optimization studies, generated a tissue microarray containing (TMA) more than 80 prostate cancer biopsy samples, and have nearly completed imaging of the TMA by MSI. Work on applying the IMC platform to the TMA is ongoing. However, using data generated to date, significant progress was made in developing a novel computational workflow to integrate and analyze high-parameter imaging data.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2022
- Accession Number
- AD1180697
Entities
People
- Patrick M. Reeves
Organizations
- Massachusetts General Hospital